comparemela.com

Latest Breaking News On - Prnewswire soligenix inc - Page 8 : comparemela.com

Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma

Results Confirm and Extend Response Results from Phase 3 FLASH Study PRINCETON, N.J., May 4, 2023 /PRNewswire/ Soligenix, Inc. , a late-stage biopharmaceutical company focused on developing and. | May 4, 2023

Brian poligoneChristopherj schaberDrug administrationExchange commissionDevelopment authorityPrnewswire soligenix incUs congressDefense threat reduction agencyEuropean medicines agencyWhile the companyBiomedical advanced researchUs developmentSoligenix incNational institute of allergyOur public health solutionsRochester skin lymphoma medical group

Soligenix Submits Type A Meeting Request to U S FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma

Meeting expected to occur approximately 30 days from the FDA s receipt of meeting request PRINCETON, N.J., April 24, 2023 /PRNewswire/ Soligenix, Inc. , a late-stage biopharmaceutical. | June 18, 2023

United statesChristopherj schaberExchange commissionBiomedical advanced researchOur public health solutionsSoligenix incPrnewswire soligenix incUs congressEuropean medicines agencyWhile the companyDrug administrationUs developmentDevelopment authorityDefense threat reduction agencyNational institute of allergyMeeting request

Soligenix Provides Regulatory Update on HyBryte™

/PRNewswire/ Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing.

United statesChristopherj schaberPrnewswire soligenix incExchange commissionBiomedical advanced researchNational institute of allergySoligenix incEuropean medicines agencyUs developmentDrug administrationOur public health solutionsDefense threat reduction agencyUs congressDevelopment authorityChief executive officerAbout cutaneoust cell lymphoma

Soligenix Receives USAN Approval for Hypericin Sodium as Nonproprietary Name for Novel Active Ingredient in HyBryte™ and SGX302

/PRNewswire/ Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing.

United statesChristopherj schaberWhile the companyUs congressOur public health solutionsUs pharmacopeial conventionDevelopment authorityInternational nonproprietary name programDrug administrationInternational drug namesBiomedical advanced researchPrnewswire soligenix incSoligenix incExchange commissionWorld health organizationUs development

Soligenix Announces Scheduling of Type A Meeting with the U S FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma

/PRNewswire/ Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing.

United statesChristopherj schaberUs congressSoligenix incNational institute of allergyWhile the companyDefense threat reduction agencyDevelopment authorityUs developmentEuropean medicines agencyBiomedical advanced researchExchange commissionOur public health solutionsDrug administrationPrnewswire soligenix incOutcome expected

vimarsana © 2020. All Rights Reserved.